中源协和细胞基因工程股份有限公司 2023年年度股东大会 会议资料 2024 年 5 月 20 日 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开 当日 9:15-15:00。 中源协和细胞基因工程股份有限公司 2023 年年度股东大会会议议程 现场会议时间：2024 年 5 月 20 日（星期一）上午 9:30。 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间9:15-9:25,9:30-11:30， 会议地点：天津市滨海高新区华苑产业区梅苑路 12 号公司会议室。 会议出席人： 1、2024 年 5 月 13 日（星期一）下午 3:00 收市后在中国证券登记结算有限 责任公司上海分公司登记在册的公司股东及股东代理人； 2、本公司董事、监事及高级管理人员； 3、本公司聘请的股东大会见证律师。 会议议程： 四、审议各项议案，股东提问与解答； | 编号 | 议案内容 | | --- | --- | | 1 | 《公司 2023 年度董事会工作报告》 | | 2 | 《公司 2023 年度监事会工作报告》 | | 3 | 《公司 20 ...

证券代码：600645 证券简称：中源协和 公告编号：2024-022 中源协和细胞基因工程股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 地点：中国证券报中证网（https://www.cs.com.cn/roadshow/yjsmh/） 方式：网络视频播放和网络文字互动 ●召开时间：2024年5月21日（星期二）15:00-16:30 ●召开地点：中国证券报中证网 （https://www.cs.com.cn/roadshow/yjsmh/） ●召开方式：网络视频播放和网络文字互动 ● 投资者 可 在 2024 年 5 月 20 日 17:00 前 通过公司邮箱 zhongyuanxiehe@vcanbio.com进行提问，公司将在业绩说明会上对投资者普遍 关注的问题进行回答。或在召开当天15:00-16:30登录中国证券报中证网参与本 次互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2024年4月26 日发布了20 ...

证券代码：600645 证券简称：中源协和 公告编号：2024-021 中源协和细胞基因工程股份有限公司 股票交易异常波动公告 二、公司关注并核实的相关情况 1、经自查，公司日常经营情况及外部环境未发生重大变化，不存在应披露 而未披露的重大信息。 2、2024 年 2 月 17 日，公司召开十一届九次临时董事会会议，审议通过 《关于以集中竞价交易方式回购股份方案的议案》，同意公司以自有资金通过集 中竞价交易方式回购公司股份，回购资金总额为不低于人民币 1 亿元（含本 数）且不超过人民币 2 亿元（含本数）。截至 2024 年 4 月 30 日，公司已累计回 购公司股份 7,707,940 股，占公司总股本的比例为 1.65%，购买的最高价为 17.95 元/股，最低价为 15.11 元/股，已支付的总金额为 125,389,095.38 元 （不含交易佣金等费用）。回购具体内容详见公司公告：2024-002、004、005、 006、008、009、010、011、020。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要 ...

关于中源协和细胞基因工程股份有限公司 中源协和细胞基因工程股份有限公司: 本企业于 2024年5月9日收到贵公司发来的问询函,现就函中问询事项回 复如下: 1、截至目前本企业及实际控制人不存在筹划涉及贵公司的重大事项以及涉 及贵公司应披露而未披露的重大信息,包括但不限于重大资产重组、股份发行、 重大交易类事项、业务重组、股权激励、破产重整、重大业务合作、引进战略投 资者等重大事项。 2、本企业及一致行动人未在 2024年5月7日、5月8日和5月9日买卖贵 公司股票。 特此说明。 深圳嘉 限合伙) 股票交易异常波动问询函的回函 ...

证券代码：600645 证券简称：中源协和 公告编号：2024-020 中源协和细胞基因工程股份有限公司 关于股份回购进展公告 本次回购资金总额为不低于人民币 1 亿元（含本数）且不超过人民币 2 亿元 （含本数），其中拟使用自有资金 5,000 万元（含本数）-10,000 万元（含本数） 回购公司股份，维护公司价值及股东权益（出售），拟使用自有资金 5,000 万元（含 本数）-10,000 万元（含本数）回购公司股份，用于实施股权激励；回购价格不超 过人民币 22 元/股（含本数）；维护公司价值及股东权益所必需（出售）的回购期 限为自董事会审议通过回购股份方案之日起不超过 3 个月，用于股权激励的回购 期限为自董事会审议通过回购股份方案之日起不超过 12 个月。 具体内容详见公司公告：2024-002、004、005、006、008、009、010、011。 二、 回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关 规定，现将本次回购方案实施进展情况公告如下： 2024 年 4 月，公司通过集中竞价交易方式已累计回购公司股份 4,238,040 股， 占公司总股本 ...

Financial Performance - The company's audited net profit for 2023 is -80.69 million RMB, with cumulative undistributed profits of -293 million RMB as of December 31, 2023, indicating no conditions for dividend distribution [7]. - The company's operating revenue for 2023 is approximately 1.59 billion RMB, representing a 2.24% increase compared to 2022 [23]. - The net profit attributable to shareholders of the listed company for 2023 is approximately 106.45 million RMB, a decrease of 5.78% from the previous year [23]. - The net cash flow from operating activities for 2023 was CNY 299,015,343.95, an increase of 14.18% compared to CNY 261,890,840.41 in 2022 [24]. - The net assets attributable to shareholders of the listed company increased by 3.61% to CNY 3,684,062,269.13 at the end of 2023, up from CNY 3,555,802,379.28 at the end of 2022 [24]. - The total assets rose by 2.40% to CNY 5,411,355,244.74 in 2023, compared to CNY 5,284,619,414.55 in 2022 [24]. - Basic earnings per share decreased by 4.17% to CNY 0.23 in 2023, down from CNY 0.24 in 2022 [25]. - The weighted average return on net assets was 2.94% in 2023, a decrease of 0.29 percentage points from 3.23% in 2022 [25]. - The company reported a total of seven IND approvals for mesenchymal stem cell new drug applications, ranking first in the country [34]. - The company’s subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval for six clinical trial indications for its VUM02 injection, including treatment for severe COVID-19 [34]. Research and Development - The company’s R&D investment reached CNY 203.57 million in 2023, representing 12.81% of total revenue, an increase from 10.21% in 2022 [43]. - The company launched the second-generation fully automated immunohistochemistry staining device, Ultra 60 Plus, enhancing staining quality and efficiency, contributing to the growth of its pathology diagnosis business [45]. - The company is actively advancing clinical trial applications for its nucleic acid mass spectrometry lung cancer and colorectal cancer targeted drug screening kits, with all clinical trials for the tissue kit completed [47]. - The company aims to enhance its core capabilities through digitalization and innovation, focusing on a full industry chain from "precise prevention + precise diagnosis + cell therapy" to a stronger industrial chain [38]. - The company is focusing on the development of innovative therapies such as stem cell and gene therapies, as highlighted in national development plans [55]. Market and Competitive Position - The company has established a strong customer base, including major institutions like Yale, Harvard, and the National Institutes of Health, enhancing its competitive advantage in the research and diagnostic markets [67]. - The company is expanding its operations in key regions such as Beijing-Tianjin-Hebei, Yangtze River Delta, and Pearl River Delta, focusing on high-net-worth clients with specialized health services [64]. - The global life science reagent market reached $17.5 billion in 2019 and is expected to grow to $24.6 billion by 2024, with a significant portion of customers being research institutions [67]. - The company is actively exploring adult cell storage while continuing to develop newborn cell storage, focusing on key regions such as Beijing-Tianjin-Hebei and the Yangtze River Delta [118]. Corporate Governance - The company adheres to strict governance practices, ensuring compliance with laws and regulations to protect shareholder rights [139]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure [140]. - The company maintains effective communication with investors through various channels, enhancing transparency and investor relations [141]. - The company has established a compensation and assessment committee responsible for reviewing and recommending remuneration policies [160]. - The company has a structured process for determining the remuneration of its directors and supervisors, which involves shareholder meetings [160]. Environmental Responsibility - The company has implemented a 24-hour operational activated carbon adsorption facility for waste gas treatment, with emissions released through a 15-meter high chimney [193]. - The company has established a hazardous waste storage facility of 30 square meters, with all hazardous waste disposed of by qualified third parties, in compliance with national and local standards [189]. - The company has received environmental permits and approvals from relevant authorities, including a new pollution discharge permit approved on October 10, 2023 [194]. - The company has established an online monitoring system for wastewater and waste gas, ensuring compliance with environmental regulations and enabling real-time management of pollutant emissions [196]. Future Outlook - The company plans to create conditions for shareholder returns in 2024, pending the release of specific operational guidelines for using capital reserves to offset losses [8]. - The company aims to enhance its cell storage and in vitro diagnostic services, focusing on quality management and precision medicine strategies [125]. - The company plans to strengthen stem cell storage and clinical applications, targeting liver diseases, respiratory diseases, autoimmune diseases, and reproductive health [126]. - The company will continue to innovate its business model in cell storage, enhancing customer experience and optimizing its sales network [127]. - Overall, the company remains optimistic about future growth, with a long-term target of achieving 3 billion in revenue by 2025 [155].

Financial Position - Total assets at the end of the reporting period were CNY 5,366,092,484, a decrease of 0.84% compared to the end of the previous year[8]. - Equity attributable to shareholders of the listed company was CNY 3,660,102,848.95, down 0.65% from the previous year[8]. - Long-term equity investments amounted to CNY 213,663,052.13, a slight decrease from CNY 216,938,901.85[14]. - Other equity instrument investments increased to CNY 456,862,467.76 from CNY 454,328,054.74[14]. - The total liabilities included contract liabilities of CNY 1,129,632,678.33, slightly down from CNY 1,134,216,178.42[14]. - Total liabilities decreased from RMB 1,612,743,955.98 to RMB 1,590,089,692.84, a reduction of approximately 1.0%[27]. - Non-current liabilities decreased from RMB 131,006,703.81 to RMB 126,427,284.42, a decrease of about 3.5%[27]. - The total equity attributable to shareholders decreased from RMB 3,684,062,269.13 to RMB 3,660,102,848.95, a decline of approximately 0.65%[27]. - The company's capital reserve remained stable at RMB 3,377,070,202.21, with a slight decrease in the previous period[27]. - The deferred income tax liabilities decreased from RMB 23,151,133.57 to RMB 22,432,553.08, a reduction of approximately 3.1%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 35,081[10]. - The top shareholder, Tianjin Deyuan Health Management Co., Ltd., holds 12.14% of the shares, totaling 56,787,503 shares[23]. - The total number of shareholders at the end of the reporting period was not specified, but the report indicates changes in the top ten shareholders due to stock lending activities[61]. Income and Profitability - The company reported a net loss of RMB 277,282,776.96, an improvement from a loss of RMB 317,432,265.76 in the previous period[27]. - The company's total operating revenue for Q1 2024 was CNY 397,981,195.71, representing a year-over-year increase of 5.36%[45]. - The net profit attributable to shareholders of the listed company was CNY 40,149,488.80, up 7.43% compared to the same period last year[45]. - The total profit for Q1 2024 was ¥56,753,233.47, compared to ¥48,689,834.90 in Q1 2023, indicating a year-over-year increase of about 16.5%[67]. - The company's operating profit reached ¥56,740,467.97, up from ¥48,502,742.39 in the previous year, marking a growth of approximately 17%[67]. - The net profit attributable to shareholders of the parent company was ¥40,149,488.80, compared to ¥37,373,824.55 in Q1 2023, reflecting an increase of around 7.5%[67]. - The total comprehensive income attributable to the parent company's owners was CNY 33,380,014.46, compared to CNY 25,156,748.58 in the same period last year[54]. - The company reported a total comprehensive income of ¥34,730,937.04 for Q1 2024, compared to ¥23,039,552.43 in the same quarter last year, showing a significant increase of approximately 50.6%[67]. Cash Flow and Expenses - Cash inflow from operating activities was RMB 401,420,062.09, slightly down from RMB 402,970,860.77 in the previous year[39]. - The cash received from sales of goods and services was RMB 391,988,309.76, compared to RMB 396,302,851.84 in the previous year, indicating a decrease of about 1.0%[39]. - The net cash flow from operating activities was CNY 21,424,807.24, a decrease of 20.74% year-over-year[45]. - The net cash flow from investing activities was CNY -20,377,150.14, showing a slight improvement from CNY -22,644,005.19 in the previous year[45]. - Research and development expenses for Q1 2024 amounted to CNY 43,793,779.30, compared to CNY 33,453,290.77 in the same period last year[53]. - The total operating costs for Q1 2024 were CNY 337,152,485.72, an increase from CNY 323,064,529.03 in Q1 2023[53]. Share Repurchase and Future Plans - The company has repurchased a total of 6,181,212 shares, representing 1.32% of the total share capital, with a total expenditure of approximately RMB 99,995,028.04[33]. - The company plans to continue using RMB 50 million to RMB 100 million for share repurchase to support stock incentives[33]. Tax and Other Comprehensive Income - The income tax expense for Q1 2024 was ¥15,252,822.09, up from ¥13,433,206.50 in Q1 2023, which is an increase of about 13.5%[67]. - The company recorded other comprehensive income after tax of -¥6,769,474.34, an improvement from -¥12,217,075.97 in the previous year[67]. - The company did not identify any non-recurring gains or losses that were significant for this reporting period[59]. - The report does not provide specific guidance on future performance or new product developments[68].

中源协和细胞基因工程股份有限公司 审计报告 大华审字【2024】0011007685 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 中源协和细胞基因工程股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-105 | 大华会计师事务所（特殊普通合伙） 北京市海淀区西 ...

中源协和细胞基因工程股份有限公司 内部控制审计报告 中源协和细胞基因工程股份有限公司 内部控制审计报告 （截止 2023 年 12 月 31 日） 目 录 页 次 大华内字【2024】0011000195 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 一、 内部控制审计报告 1-2 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 ...

公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2023 年度内部控制评价报告 中源协和细胞基因工程股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外， ...